Fisher Asset Management LLC increased its stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 22.9% during the 3rd quarter, Holdings Channel reports. The firm owned 213,131 shares of the biopharmaceutical company’s stock after purchasing an additional 39,727 shares during the quarter. Fisher Asset Management LLC’s holdings in Bristol Myers Squibb were worth $13,299,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of BMY. PBU The Pension Fund of Early Childhood & Youth Educators lifted its holdings in shares of Bristol Myers Squibb by 6.4% during the 3rd quarter. PBU The Pension Fund of Early Childhood & Youth Educators now owns 233,660 shares of the biopharmaceutical company’s stock worth $14,580,000 after acquiring an additional 13,968 shares during the last quarter. R Squared Ltd bought a new stake in shares of Bristol Myers Squibb in the 3rd quarter worth approximately $328,000. King Luther Capital Management Corp lifted its holdings in shares of Bristol Myers Squibb by 1.7% in the 3rd quarter. King Luther Capital Management Corp now owns 606,134 shares of the biopharmaceutical company’s stock worth $37,823,000 after acquiring an additional 9,890 shares during the last quarter. Maryland State Retirement & Pension System lifted its holdings in shares of Bristol Myers Squibb by 12.5% in the 3rd quarter. Maryland State Retirement & Pension System now owns 124,534 shares of the biopharmaceutical company’s stock worth $7,771,000 after acquiring an additional 13,837 shares during the last quarter. Finally, Ritholtz Wealth Management boosted its stake in shares of Bristol Myers Squibb by 31.6% in the 3rd quarter. Ritholtz Wealth Management now owns 223,042 shares of the biopharmaceutical company’s stock valued at $13,918,000 after purchasing an additional 53,567 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on BMY shares. Cantor Fitzgerald dropped their target price on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating for the company in a report on Thursday, October 8th. Zacks Research lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 22nd. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Wells Fargo & Company cut their price objective on shares of Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating on the stock in a report on Tuesday, October 13th. Finally, Bank of America reissued a “buy” rating on shares of Bristol Myers Squibb in a research note on Friday, October 30th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $65.46.
Get Our Latest Stock Analysis on BMY
Insider Buying and Selling at Bristol Myers Squibb
In other Bristol Myers Squibb news, Director Julia A. Haller sold 3,800 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the sale, the director directly owned 30,279 shares of the company’s stock, valued at approximately $1,916,963.49. This represents a 11.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.05% of the company’s stock.
Trending Headlines about Bristol Myers Squibb
Investors following BMY have been watching these headlines:
- Positive Sentiment: Bristol Myers is working to expand Camzyos’ reach, while Eliquis remains an important contributor to its cardiovascular franchise. Sustained growth in these products could help support revenue. Can BMY Sustain Growth in Its Cardiovascular Franchise?
- Neutral Sentiment: The company plans to unify research and development under one structure, aiming to bring scientific and clinical teams together to speed development and use new technologies. The departure of research chief Robert Plenge adds transition risk, so the impact will depend on execution. BMS sets unified research and development structure for 2027
- Negative Sentiment: Zacks Research cut several earnings forecasts, including FY2026 EPS to $6.44 from $6.86 and FY2028 EPS to $4.77 from $5.21; it also reduced its Q4 2026 and Q2 2027 estimates. These revisions point to a softer earnings outlook, although the firm maintained a Hold rating. Bristol Myers Squibb analyst estimates
Bristol Myers Squibb Stock Down 0.1%
BMY stock opened at $63.39 on Monday. The stock has a market capitalization of $129.57 billion, a P/E ratio of 14.06, a P/E/G ratio of 0.33 and a beta of 0.20. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. Bristol Myers Squibb Company has a 1-year low of $45.26 and a 1-year high of $68.64. The business has a fifty day moving average price of $61.90 and a 200-day moving average price of $60.31.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The company had revenue of $13.07 billion for the quarter, compared to analysts’ expectations of $12.72 billion. During the same period last year, the firm posted $1.63 earnings per share. Bristol Myers Squibb’s revenue was up 6.9% compared to the same quarter last year. Equities analysts forecast that Bristol Myers Squibb Company will post 6.46 earnings per share for the current fiscal year.
Bristol Myers Squibb Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb’s payout ratio is 55.88%.
Bristol Myers Squibb Company Profile
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Featured Stories
- Five stocks we like better than Bristol Myers Squibb
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
